HUM Misses Q2 Earnings on Higher Benefit Costs, Ups '25 EPS View

Humana (HUM) reported Q2 2025 adjusted EPS of $6.27, missing analyst estimates by 0.8% and representing a 9.9% year-over-year decline, primarily due to elevated benefit costs and a reduction in individual Medicare Advantage membership. Despite this, the company's adjusted revenues rose 10.2% to $32.4 billion, surpassing consensus, bolstered by strong performance from its CenterWell unit. Looking ahead, Humana raised its full-year 2025 adjusted EPS guidance to approximately $17.00 and increased its revenue forecast to at least $128 billion, signaling management's confidence despite the quarterly setback.

Analysis

Humana's second-quarter 2025 results present a conflicting narrative, defined by current profitability pressures offset by an optimistic forward outlook. The company's adjusted EPS of $6.27 missed consensus estimates and declined 9.9% year-over-year, primarily driven by higher benefit costs that caused the benefit ratio to deteriorate by 70 basis points to 89.7%. This pressure was compounded by a significant 9% year-over-year tumble in total medical membership to 14.8 million, indicating persistent headwinds in its core Insurance segment. However, these negatives were partially mitigated by a 10.2% increase in adjusted revenues to $32.4 billion, which beat expectations, and the strong performance of its CenterWell unit, where revenues climbed 11.9%. Crucially, management signaled confidence by raising its full-year 2025 adjusted EPS guidance to approximately $17.00 and its revenue forecast to a minimum of $128 billion, suggesting a belief that the cost and membership issues can be managed effectively through the remainder of the year.

Key Decisions for Investors

• Investors should weigh the positive signal from the upgraded full-year 2025 adjusted EPS and revenue guidance against the significant current-quarter profitability pressures, including the 9.9% EPS drop and deteriorating benefit ratio.
• Closely monitor the performance of the CenterWell segment, whose 11.9% revenue growth serves as a key offset to the challenges in the core insurance business, particularly the 9% decline in medical membership.
• Given that peers like HCA Healthcare and Tenet Healthcare reported strong earnings beats, consider whether Humana's high benefit costs are a company-specific execution issue rather than a broad sector-wide trend.
• Factor in the company's continued capital return policy, including a $2.83 billion share buyback authorization, which provides a degree of support for the stock despite the operational headwinds.